share_log

Mangoceuticals | CORRESP: CORRESP

Mangoceuticals | CORRESP: CORRESP

Mangoceuticals | CORRESP:信函
美股SEC公告 ·  09/03 12:49

Moomoo AI 已提取核心訊息

Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on August 16, 2024. The company seeks to have the registration become effective at 4:30 p.m. EDT on September 5, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. The correspondence, signed by Chairman and CEO Jacob D. Cohen, indicates Mangoceuticals' intention to move forward with its registration as soon as practicable.
Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on August 16, 2024. The company seeks to have the registration become effective at 4:30 p.m. EDT on September 5, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. The correspondence, signed by Chairman and CEO Jacob D. Cohen, indicates Mangoceuticals' intention to move forward with its registration as soon as practicable.
Mangoceuticals公司已正式請求美國證券交易委員會(SEC)加快生效其於2024年8月16日初次提交的S-1表格註冊聲明。 該公司希望註冊在2024年9月5日下午4:30 EDT生效。此請求根據1933年證券法修正案的第461條規定提出。董事長兼首席執行官Jacob D. Cohen簽署的函件表明Mangoceuticals打算在儘快時實行其註冊。
Mangoceuticals公司已正式請求美國證券交易委員會(SEC)加快生效其於2024年8月16日初次提交的S-1表格註冊聲明。 該公司希望註冊在2024年9月5日下午4:30 EDT生效。此請求根據1933年證券法修正案的第461條規定提出。董事長兼首席執行官Jacob D. Cohen簽署的函件表明Mangoceuticals打算在儘快時實行其註冊。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息